Talia Kaden, MD
Ophthalmology · New York, NYNPI 1770825689
Payments from drug & device makers
Across 95 payments — averaging $774.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$19K
- Genentech USA, Inc.$16K
- Apellis Pharmaceuticals, Inc.$10K
- AbbVie$9K
- F. Hoffmann-la Roche AG$7K
- Regeneron$5K
- plus $7K from 10 others
Across 2 payments — averaging $935.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
- Regeneron$449
What the payments were for
- Consulting fees$61,74484%
- Travel & lodging$6,2058%
- Food & beverage$5,6588%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 8 | $19,151 |
| Genentech USA, Inc. | 17 | $15,682 |
| Apellis Pharmaceuticals, Inc. | 20 | $10,179 |
| AbbVie | 18 | $9,474 |
| F. Hoffmann-la Roche AG | 5 | $7,230 |
| Regeneron | 9 | $4,905 |
| Genentech, Inc. | 3 | $3,100 |
| Alcon Research LLC | 2 | $2,500 |
| Alcon | 4 | $634 |
| Dutch Ophthalmic, USA | 2 | $316 |
| Novartis | 1 | $102 |
| Astellas Pharma US Inc | 2 | $84 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $81 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Regeneron Healthcare Solutions, Inc. | 1 | $54 |
| Alimera Sciences, Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$22,365
- OZURDEX$9,140
- Syfovre$8,963
- Lucentis$5,177
- EYLEA HD$3,745
- EVA, combined machine$171
- TISSUEBLUE$171
- EVA Ophthalmic Surgical System$145
How this compares
$73,607 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 97 | $6,306 |
| Ketorolac Tromethamine | 26 | $891 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $388 |
| Timolol Maleate | 25 | $313 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.